The path to first patient dosing

• Screening for first patient dosing in ALA-101 study underway
• First patient dosing expected in October
• Trial focuses on CD19-positive non-Hodgkin lymphoma and leukaemia

Arovella Therapeutics Ltd (ASX: ALA) is in the process of screening patients to identify eligibility for its phase 1 ALA-101 study, with the first patient dosing anticipated towards the end of October 2026. The trial, a first-in-human study, will evaluate ALA-101 in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and leukaemia. The study involves detailed assessments and screenings at The Alfred Hospital, ensuring that only eligible patients are enrolled. The revised dosing timetable is due to the stringent eligibility criteria required for a first-in-human cellular therapy trial, rather than patient availability or demand.